A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: Many options, no standards
- PMID:26685719
- DOI: 10.1016/j.jaad.2015.09.062
A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: Many options, no standards
Abstract
Background: Investigators often use global assessments to provide a snapshot of overall disease severity in dermatologic clinical trials. Although easy to perform, the frequency of use and standardization of global assessments in studies of atopic dermatitis (AD) is unclear.
Objectives: We sought to assess the frequency, definitions, and methods of analysis of Investigator Global Assessment in randomized controlled trials of AD.
Methods: We conducted a systematic review using all published randomized controlled trials of AD treatments in the Global Resource of Eczema Trials database (2000-2014). We determined the frequency of global scales application and defining features.
Results: Among 317 trials identified, 101 trials (32%) used an investigator-performed global assessment as an outcome measure. There was large variability in global assessments between studies in nomenclature, scale size, definitions, outcome description, and analysis. Both static and dynamic scales were identified that ranged from 4- to 7-point scales. North American studies used global assessments more commonly than studies from other countries.
Limitations: The search was restricted to the Global Resource of Eczema Trials database.
Conclusion: Global assessments are used frequently in studies of AD, but their complete lack of standardized definitions and implementation preclude any meaningful comparisons between studies, which in turn impedes data synthesis to inform clinical decision-making. Standardization is urgently required.
Keywords: Investigator Global Assessment; atopic dermatitis; atopic eczema; global assessment; outcome measure; randomized controlled trial; severity; systematic review.
Copyright © 2015. Published by Elsevier Inc.
Similar articles
- The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis.Simpson E, Bissonnette R, Eichenfield LF, Guttman-Yassky E, King B, Silverberg JI, Beck LA, Bieber T, Reich K, Kabashima K, Seyger M, Siegfried E, Stingl G, Feldman SR, Menter A, van de Kerkhof P, Yosipovitch G, Paul C, Martel P, Dubost-Brama A, Armstrong J, Chavda R, Frey S, Joubert Y, Milutinovic M, Parneix A, Teixeira HD, Lin CY, Sun L, Klekotka P, Nickoloff B, Dutronc Y, Mallbris L, Janes JM, DeLozier AM, Nunes FP, Paller AS.Simpson E, et al.J Am Acad Dermatol. 2020 Sep;83(3):839-846. doi: 10.1016/j.jaad.2020.04.104. Epub 2020 Apr 25.J Am Acad Dermatol. 2020.PMID:32344071
- The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): a clinical outcome measure for the severity of atopic dermatitis.Simpson EL, Bissonnette R, Paller AS, King B, Silverberg JI, Reich K, Thyssen JP, Doll H, Sun L, DeLozier AM, Nunes FP, Eichenfield LF.Simpson EL, et al.Br J Dermatol. 2022 Oct;187(4):531-538. doi: 10.1111/bjd.21615. Epub 2022 Aug 21.Br J Dermatol. 2022.PMID:35442530Free PMC article.
- Assessing the severity of atopic dermatitis in clinical trials and practice.Chopra R, Silverberg JI.Chopra R, et al.Clin Dermatol. 2018 Sep-Oct;36(5):606-615. doi: 10.1016/j.clindermatol.2018.05.012. Epub 2018 Jun 1.Clin Dermatol. 2018.PMID:30217273Review.
- Severity assessments used for inclusion criteria and baseline severity evaluation in atopic dermatitis clinical trials: a systematic review.Chopra R, Vakharia PP, Simpson EL, Paller AS, Silverberg JI.Chopra R, et al.J Eur Acad Dermatol Venereol. 2017 Nov;31(11):1890-1899. doi: 10.1111/jdv.14483. Epub 2017 Sep 14.J Eur Acad Dermatol Venereol. 2017.PMID:28750145Review.
- Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, Tilley B, Sacks D; Technology Assessment Committee of the American Society of Interventional and Therapeutic Neuroradiology; Technology Assessment Committee of the Society of Interventional Radiology.Higashida RT, et al.Stroke. 2003 Aug;34(8):e109-37. doi: 10.1161/01.STR.0000082721.62796.09. Epub 2003 Jul 17.Stroke. 2003.PMID:12869717
Cited by
- Application of Janus Kinase Inhibitors in Atopic Dermatitis: An Updated Systematic Review and Meta-Analysis of Clinical Trials.Tsai HR, Lu JW, Chen LY, Chen TL.Tsai HR, et al.J Pers Med. 2021 Apr 7;11(4):279. doi: 10.3390/jpm11040279.J Pers Med. 2021.PMID:33917069Free PMC article.Review.
- An Interim Report of a Phase 3, Long-Term, Open-Label Study to Evaluate Efficacy and Safety of Difamilast Ointment in Japanese Infants with Atopic Dermatitis.Saeki H, Ohya Y, Baba N, Imamura T, Yokota D, Tsubouchi H.Saeki H, et al.Dermatol Ther (Heidelb). 2024 Sep;14(9):2443-2455. doi: 10.1007/s13555-024-01236-7. Epub 2024 Jul 29.Dermatol Ther (Heidelb). 2024.PMID:39075274Free PMC article.
- Treatment of Atopic Dermatitis Using a Full-Body Blue Light Device (AD-Blue): Protocol of a Randomized Controlled Trial.Kromer C, Nühnen VP, Pfützner W, Pfeiffer S, Laubach HJ, Boehncke WH, Liebmann J, Born M, Schön MP, Buhl T.Kromer C, et al.JMIR Res Protoc. 2019 Jan 8;8(1):e11911. doi: 10.2196/11911.JMIR Res Protoc. 2019.PMID:30622089Free PMC article.
- Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis.Wan H, Jia H, Xia T, Zhang D.Wan H, et al.Dermatol Ther. 2022 Sep;35(9):e15636. doi: 10.1111/dth.15636. Epub 2022 Jul 27.Dermatol Ther. 2022.PMID:35703351Free PMC article.Review.
- Exploring content and psychometric validity of newly developed assessment tools for itch and skin pain in atopic dermatitis.Newton L, DeLozier AM, Griffiths PC, Hill JN, Hudgens S, Symonds T, Gable JC, Paik J, Wyrwich KW, Eichenfield LF, Abetz-Webb L, Silverberg JI.Newton L, et al.J Patient Rep Outcomes. 2019 Jul 16;3(1):42. doi: 10.1186/s41687-019-0128-z.J Patient Rep Outcomes. 2019.PMID:31312940Free PMC article.
Publication types
MeSH terms
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous